{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:47:15Z","timestamp":1785898035394,"version":"3.56.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s11910-017-0739-9","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T08:58:06Z","timestamp":1490086686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Huntington\u2019s Disease\u2014Update on Treatments"],"prefix":"10.1007","volume":"17","author":[{"given":"Kara J.","family":"Wyant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Dayalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,21]]},"reference":[{"issue":"6","key":"739_CR1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72(6):971\u201383.","journal-title":"Cell"},{"issue":"3","key":"739_CR2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jchemneu.2004.02.005","volume":"27","author":"YP Deng","year":"2004","unstructured":"Deng YP, et al. Differential loss of striatal projection systems in Huntington\u2019s disease: a quantitative immunohistochemical study. J Chem Neuroanat. 2004;27(3):143\u201364.","journal-title":"J Chem Neuroanat"},{"issue":"15","key":"739_CR3","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","volume":"85","author":"A Reiner","year":"1988","unstructured":"Reiner A, et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci. 1988;85(15):5733\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"739_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd2784","volume":"8","author":"MR Hayden","year":"2009","unstructured":"Hayden MR, et al. Tetrabenazine. Nat Rev Drug Discov. 2009;8(1):17\u20138.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"739_CR5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/mds.25278","volume":"28","author":"R Mehanna","year":"2013","unstructured":"Mehanna R, et al. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210\u20135.","journal-title":"Mov Disord"},{"issue":"2","key":"739_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","volume":"22","author":"C Kenney","year":"2007","unstructured":"Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193\u20137.","journal-title":"Mov Disord"},{"issue":"3","key":"739_CR7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366\u201372.","journal-title":"Neurology"},{"key":"739_CR8","first-page":"62","volume":"9","author":"S Frank","year":"2009","unstructured":"Frank S. Huntington Study Group\/TETRA-HD investigators. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study BMC Neurol. 2009;9:62.","journal-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study BMC Neurol"},{"issue":"6","key":"739_CR9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","volume":"31","author":"A Fasano","year":"2008","unstructured":"Fasano A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol. 2008;31(6):313\u20138.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"739_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/WNF.0b013e3180ca77ea","volume":"31","author":"S Frank","year":"2008","unstructured":"Frank S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31(3):127\u201333.","journal-title":"Clin Neuropharmacol"},{"key":"739_CR11","doi-asserted-by":"crossref","unstructured":"Shen V, et al. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington\u2019s and other diseases. Tremor Other Hyperkinet Mov. 2013;3","DOI":"10.5334\/tohm.129"},{"issue":"4","key":"739_CR12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JHD-130071","volume":"2","author":"ER Dorsey","year":"2013","unstructured":"Dorsey ER, et al. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. J Huntingtons Dis. 2013;2(4):509\u201315.","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"739_CR13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"\u2022\u2022 Frank S, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40\u201350. A recent trial testing a novel molecule containing deuterium bound to tetrabenazine (TBZ), used to prolong the half-life of TBZ and decrease the side effects. This new medication could potentially allow for better control of chorea with fewer side effects","journal-title":"JAMA"},{"issue":"7890","key":"739_CR14","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(74)90847-2","volume":"2","author":"DP Leonard","year":"1974","unstructured":"Leonard DP, et al. Letter: double-blind trial of lithium carbonate and haloperidol in Huntington\u2019s chorea. Lancet. 1974;2(7890):1208\u20139.","journal-title":"Lancet"},{"issue":"10","key":"739_CR15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.31.10.1333","volume":"31","author":"I Shoulson","year":"1981","unstructured":"Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology. 1981;31(10):1333\u20135.","journal-title":"Neurology"},{"key":"739_CR16","first-page":"573","volume":"24","author":"R Arena","year":"1980","unstructured":"Arena R, et al. Huntington\u2019s disease: clinical effects of a short-term treatment with pimozide. Adv Biochem Psychopharmacol. 1980;24:573\u20135.","journal-title":"Adv Biochem Psychopharmacol"},{"issue":"2","key":"739_CR17","first-page":"177","volume":"20","author":"CF Terrence","year":"1976","unstructured":"Terrence CF. Fluphenazine decanoate in the treatment of chorea: a double-blind study. Curr Ther Res Clin Exp. 1976;20(2):177\u201383.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"1","key":"739_CR18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","volume":"63","author":"JP Vugt van","year":"1997","unstructured":"van Vugt JP, et al. Clozapine versus placebo in Huntington\u2019s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry. 1997;63(1):35\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"739_CR19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1212\/WNL.44.5.821","volume":"44","author":"U Bonuccelli","year":"1994","unstructured":"Bonuccelli U, et al. Clozapine in Huntington\u2019s chorea. Neurology. 1994;44(5):821\u20133.","journal-title":"Neurology"},{"issue":"5","key":"739_CR20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","volume":"25","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington\u2019s disease: an open label study. Clin Neuropharmacol. 2002;25(5):263\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"739_CR21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","volume":"105","author":"D Paleacu","year":"2002","unstructured":"Paleacu D, Anca M, Giladi N. Olanzapine in Huntington\u2019s disease. Acta Neurol Scand. 2002;105(6):441\u20134.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"739_CR22","first-page":"69","volume":"14","author":"F Squitieri","year":"2001","unstructured":"Squitieri F, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(1):69\u201372.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"1","key":"739_CR23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","volume":"24","author":"L Brusa","year":"2009","unstructured":"Brusa L, et al. Treatment of the symptoms of Huntington\u2019s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord. 2009;24(1):126\u20139.","journal-title":"Mov Disord"},{"issue":"8","key":"739_CR24","first-page":"1353","volume":"98","author":"ES Cankurtaran","year":"2006","unstructured":"Cankurtaran ES, et al. Clinical experience with risperidone and memantine in the treatment of Huntington\u2019s disease. J Natl Med Assoc. 2006;98(8):1353\u20135.","journal-title":"J Natl Med Assoc"},{"issue":"2","key":"739_CR25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","volume":"9","author":"AK Erdemoglu","year":"2002","unstructured":"Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington\u2019s disease. Eur J Neurol. 2002;9(2):182\u20133.","journal-title":"Eur J Neurol"},{"issue":"2","key":"739_CR26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00004714-199704000-00023","volume":"17","author":"MA Parsa","year":"1997","unstructured":"Parsa MA, et al. Risperidone in treatment of choreoathetosis of Huntington\u2019s disease. J Clin Psychopharmacol. 1997;17(2):134\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"739_CR27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00415-002-0741-1","volume":"249","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, Niederwieser G. Quetiapine in Huntington\u2019s disease: a first case report. J Neurol. 2002;249(8):1114\u20135.","journal-title":"J Neurol"},{"issue":"4","key":"739_CR28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881103174009","volume":"17","author":"RM Bonelli","year":"2003","unstructured":"Bonelli RM, et al. Ziprasidone in Huntington\u2019s disease: the first case reports. J Psychopharmacol. 2003;17(4):459\u201360.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"739_CR29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","volume":"33","author":"A Lundin","year":"2010","unstructured":"Lundin A, et al. Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington\u2019s disease. Clin Neuropharmacol. 2010;33(5):260\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"739_CR30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG Yebenes de","year":"2011","unstructured":"de Yebenes JG, et al. Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049\u201357.","journal-title":"Lancet Neurol"},{"issue":"10","key":"739_CR31","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","volume":"28","author":"Huntington Study Group","year":"2013","unstructured":"Huntington Study Group. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord. 2013;28(10):1407\u201315.","journal-title":"Mov Disord"},{"issue":"12","key":"739_CR32","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/01.WNL.0000068165.07883.64","volume":"60","author":"C Lucetti","year":"2003","unstructured":"Lucetti C, et al. IV amantadine improves chorea in Huntington,s disease: an acute randomized, controlled study. Neurology. 2003;60(12):1995\u20137.","journal-title":"Neurology"},{"issue":"Suppl 2","key":"739_CR33","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s100720200081","volume":"23","author":"C Lucetti","year":"2002","unstructured":"Lucetti C, et al. Amantadine in Huntington\u2019s disease: open-label video-blinded study. Neurol Sci. 2002;23(Suppl 2):S83\u20134.","journal-title":"Neurol Sci"},{"issue":"5","key":"739_CR34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","volume":"59","author":"ML Verhagen","year":"2002","unstructured":"Verhagen ML, et al. Huntington\u2019s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59(5):694\u20139.","journal-title":"Neurology"},{"issue":"7","key":"739_CR35","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","volume":"60","author":"P O\u2019Suilleabhain","year":"2003","unstructured":"O\u2019Suilleabhain P, Dewey RB. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60(7):996\u20138.","journal-title":"Arch Neurol"},{"issue":"3","key":"739_CR36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","volume":"62","author":"GB Landwehrmeyer","year":"2007","unstructured":"Landwehrmeyer GB, et al. Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study. Ann Neurol. 2007;62(3):262\u201372.","journal-title":"Ann Neurol"},{"issue":"11","key":"739_CR37","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","volume":"61","author":"Huntington Study Group","year":"2003","unstructured":"Huntington Study Group. Dosage effects of riluzole in Huntington\u2019s disease: a multicenter placebo-controlled study. Neurology. 2003;61(11):1551\u20136.","journal-title":"Neurology"},{"issue":"6","key":"739_CR38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597\u2013603.","journal-title":"Neurology"},{"issue":"2","key":"739_CR39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00415-015-7968-0","volume":"263","author":"C Delorme","year":"2016","unstructured":"Delorme C, et al. Deep brain stimulation of the internal pallidum in Huntington\u2019s disease patients: clinical outcome and neuronal firing patterns. J Neurol. 2016;263(2):290\u20138.","journal-title":"J Neurol"},{"issue":"1","key":"739_CR40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3171\/2014.2.JNS131722","volume":"121","author":"V Gonzalez","year":"2014","unstructured":"\u2022 Gonzalez V, et al. Deep brain stimulation for Huntington\u2019s disease: long-term results of a prospective open-label study. J Neurosurg. 2014;121(1):114\u201322. Longitudinal case series of bilateral GPi DBS in patients with pharmacologically resistant chorea secondary to HD. Provides information about long-term outcomes of DBS therapy for chorea in HD","journal-title":"J Neurosurg"},{"issue":"3","key":"739_CR41","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/jnnp.2009.202903","volume":"82","author":"GA Kang","year":"2011","unstructured":"Kang GA, et al. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2011;82(3):272\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"739_CR42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.20183","volume":"56","author":"E Moro","year":"2004","unstructured":"Moro E, et al. Bilateral globus pallidus stimulation for Huntington\u2019s disease. Ann Neurol. 2004;56(2):290\u20134.","journal-title":"Ann Neurol"},{"issue":"2","key":"739_CR43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000341070","volume":"91","author":"FM Velez-Lago","year":"2013","unstructured":"Velez-Lago FM, et al. Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington\u2019s disease. Stereotact Funct Neurosurg. 2013;91(2):129\u201333.","journal-title":"Stereotact Funct Neurosurg"},{"issue":"2","key":"739_CR44","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parkreldis.2013.11.007","volume":"20","author":"JL Lopez-Sendon Moreno","year":"2014","unstructured":"Lopez-Sendon Moreno JL, et al. A 5-year follow-up of deep brain stimulation in Huntington\u2019s disease. Parkinsonism Relat Disord. 2014;20(2):260\u20131.","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"739_CR45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/mds.24959","volume":"27","author":"S Spielberger","year":"2012","unstructured":"Spielberger S, et al. Deep brain stimulation in Huntington\u2019s disease: a 4-year follow-up case report. Mov Disord. 2012;27(6):806\u20137. author reply 807-8","journal-title":"Mov Disord"},{"issue":"4","key":"739_CR46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jnnp.65.4.577","volume":"65","author":"BA Racette","year":"1998","unstructured":"Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 1998;65(4):577\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"739_CR47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/jnnp.68.2.238","volume":"68","author":"I Reuter","year":"2000","unstructured":"Reuter I, et al. Late onset levodopa responsive Huntington\u2019s disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry. 2000;68(2):238\u201341.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"739_CR48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0303-8467(80)90017-7","volume":"82","author":"PJ Jongen","year":"1980","unstructured":"Jongen PJ, Renier WO, Gabreels FJ. Seven cases of Huntington\u2019s disease in childhood and levodopa induced improvement in the hypokinetic\u2014rigid form. Clin Neurol Neurosurg. 1980;82(4):251\u201361.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"739_CR49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3171\/JNS\/2008\/109\/7\/0130","volume":"109","author":"B Biolsi","year":"2008","unstructured":"Biolsi B, et al. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg. 2008;109(1):130\u20132.","journal-title":"J Neurosurg"},{"issue":"5","key":"739_CR50","first-page":"355","volume":"113","author":"MK Magnet","year":"2006","unstructured":"Magnet MK, Kapfhammer HP, Bonelli RM. Cabergoline in Huntington\u2019s disease: the first case report. Acta Neurol Scand. 2006;113(5):355\u20136.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"739_CR51","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200201000-00011","volume":"25","author":"RM Bonelli","year":"2002","unstructured":"Bonelli RM, et al. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington\u2019s disease. Clin Neuropharmacol. 2002;25(1):58\u201360.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"739_CR52","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/ner.12098","volume":"17","author":"G Cislaghi","year":"2014","unstructured":"Cislaghi G, et al. Bilateral globus pallidus stimulation in Westphal variant of Huntington disease. Neuromodulation. 2014;17(5):502\u20135.","journal-title":"Neuromodulation"},{"issue":"6","key":"739_CR53","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/1531-8257(200011)15:6<1248::AID-MDS1029>3.0.CO;2-Q","volume":"15","author":"E Cubo","year":"2000","unstructured":"Cubo E, et al. Internal globus pallidotomy in dystonia secondary to Huntington\u2019s disease. Mov Disord. 2000;15(6):1248\u201351.","journal-title":"Mov Disord"},{"key":"739_CR54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-6-11","volume":"6","author":"C Saft","year":"2006","unstructured":"Saft C, et al. Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington\u2019s disease patients: a case series. BMC Neurol. 2006;6:11.","journal-title":"BMC Neurol"},{"issue":"6","key":"739_CR55","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/mds.870090609","volume":"9","author":"PD Thompson","year":"1994","unstructured":"Thompson PD, et al. Cortical myoclonus in Huntington\u2019s disease. Mov Disord. 1994;9(6):633\u201341.","journal-title":"Mov Disord"},{"issue":"2","key":"739_CR56","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ana.410290217","volume":"29","author":"CM Vogel","year":"1991","unstructured":"Vogel CM, et al. Myoclonus in adult Huntington\u2019s disease. Ann Neurol. 1991;29(2):213\u20135.","journal-title":"Ann Neurol"},{"issue":"11","key":"739_CR57","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/jnnp-2013-305114","volume":"84","author":"JS Paulsen","year":"2013","unstructured":"Paulsen JS, Smith MM, Long JD. Cognitive decline in prodromal Huntington disease: implications for clinical trials. J Neurol Neurosurg Psychiatry. 2013;84(11):1233\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"739_CR58","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1212\/WNL.45.5.951","volume":"45","author":"JS Paulsen","year":"1995","unstructured":"Paulsen JS, et al. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology. 1995;45(5):951\u20136.","journal-title":"Neurology"},{"issue":"4","key":"739_CR59","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/13803390600718958","volume":"9","author":"KF Hoth","year":"2007","unstructured":"Hoth KF, et al. Patients with Huntington\u2019s disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol. 2007;9(4):365\u201376.","journal-title":"J Clin Exp Neuropsychol"},{"issue":"1","key":"739_CR60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","volume":"30","author":"M Tommaso de","year":"2007","unstructured":"de Tommaso M, et al. Two years\u2019 follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30(1):43\u20136.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"739_CR61","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1468-1331.2002.00447_4.x","volume":"9","author":"U Rot","year":"2002","unstructured":"Rot U, et al. Rivastigmine in the treatment of Huntington\u2019s disease. Eur J Neurol. 2002;9(6):689\u201390.","journal-title":"Eur J Neurol"},{"issue":"3","key":"739_CR62","first-page":"239","volume":"26","author":"S Sesok","year":"2014","unstructured":"Sesok S, et al. Cognitive function in early clinical phase Huntington disease after rivastigmine treatment. Psychiatr Danub. 2014;26(3):239\u201348.","journal-title":"Psychiatr Danub"},{"issue":"7","key":"739_CR63","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","volume":"67","author":"E Cubo","year":"2006","unstructured":"Cubo E, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268\u201371.","journal-title":"Neurology"},{"issue":"7","key":"739_CR64","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.parkreldis.2006.08.005","volume":"13","author":"WG Ondo","year":"2007","unstructured":"Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington\u2019s disease. Parkinsonism Relat Disord. 2007;13(7):453\u20134.","journal-title":"Parkinsonism Relat Disord"},{"key":"739_CR65","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-7091-0579-5_14","volume":"68","author":"A Beister","year":"2004","unstructured":"Beister A, et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington\u2019s disease. J Neural Transm Suppl. 2004;68:117\u201322.","journal-title":"J Neural Transm Suppl"},{"issue":"3","key":"739_CR66","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.71.3.310","volume":"71","author":"JS Paulsen","year":"2001","unstructured":"Paulsen JS, et al. Neuropsychiatric aspects of Huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2001;71(3):310\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"739_CR67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1176\/jnp.10.3.314","volume":"10","author":"ML Levy","year":"1998","unstructured":"Levy ML, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci. 1998;10(3):314\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"12","key":"739_CR68","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","volume":"62","author":"K Duff","year":"2007","unstructured":"Duff K, et al. Psychiatric symptoms in Huntington\u2019s disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007;62(12):1341\u20136.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"739_CR69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01.nmd.0000106004.67587.57","volume":"192","author":"C Nehl","year":"2004","unstructured":"Nehl C, Paulsen JS. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis. 2004;192(1):72\u20134.","journal-title":"J Nerv Ment Dis"},{"issue":"12","key":"739_CR70","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","volume":"85","author":"E Duijn van","year":"2014","unstructured":"van Duijn E, et al. Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"739_CR71","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","volume":"19","author":"E Duijn van","year":"2007","unstructured":"van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington\u2019s disease gene carriers. J Neuropsychiatry Clin Neurosci. 2007;19(4):441\u20138.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"12","key":"739_CR72","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/mds.25980","volume":"29","author":"CD Moulton","year":"2014","unstructured":"Moulton CD, Hopkins CW, Bevan-Jones WR. Systematic review of pharmacological treatments for depressive symptoms in Huntington\u2019s disease. Mov Disord. 2014;29(12):1556\u201361.","journal-title":"Mov Disord"},{"issue":"3","key":"739_CR73","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.870120319","volume":"12","author":"PG Como","year":"1997","unstructured":"Como PG, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington\u2019s disease. Mov Disord. 1997;12(3):397\u2013401.","journal-title":"Mov Disord"},{"issue":"3","key":"739_CR74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.25750","volume":"29","author":"LJ Beglinger","year":"2014","unstructured":"Beglinger LJ, et al. Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord. 2014;29(3):401\u20135.","journal-title":"Mov Disord"},{"issue":"1","key":"739_CR75","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","volume":"25","author":"AK Holl","year":"2010","unstructured":"Holl AK, et al. Combating depression in Huntington\u2019s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25(1):46\u201350.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"739_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10401230701844802","volume":"20","author":"K Duff","year":"2008","unstructured":"Duff K, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington\u2019s disease. Ann Clin Psychiatry. 2008;20(1):1\u20133.","journal-title":"Ann Clin Psychiatry"},{"key":"739_CR77","first-page":"1","volume":"5","author":"A Ciammola","year":"2009","unstructured":"Ciammola A, et al. Aripiprazole in the treatment of Huntington\u2019s disease: a case series. Neuropsychiatr Dis Treat. 2009;5:1\u20134.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"739_CR78","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1212\/WNL.41.1.156","volume":"41","author":"M Sajatovic","year":"1991","unstructured":"Sajatovic M, et al. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington\u2019s chorea. Neurology. 1991;41(1):156.","journal-title":"Neurology"},{"issue":"2","key":"739_CR79","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/YIC.0b013e3283407775","volume":"26","author":"TG Johnston","year":"2011","unstructured":"Johnston TG. Risperidone long-acting injection and Huntington\u2019s disease: case series with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol. 2011;26(2):114\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"739_CR80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1176\/jnp.8.2.209","volume":"8","author":"CF Lewis","year":"1996","unstructured":"Lewis CF, DeQuardo JR, Tandon R. ECT in genetically confirmed Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci. 1996;8(2):209\u201310.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2","key":"739_CR81","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1176\/jnp.6.2.154","volume":"6","author":"NG Ranen","year":"1994","unstructured":"Ranen NG, Peyser CE, Folstein SE. ECT as a treatment for depression in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci. 1994;6(2):154\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"6","key":"739_CR82","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.genhosppsych.2013.01.015","volume":"35","author":"C Cusin","year":"2013","unstructured":"Cusin C, et al. Rapid improvement of depression and psychotic symptoms in Huntington\u2019s disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. Gen Hosp Psychiatry. 2013;35(6):678. e3-5","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"739_CR83","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1176\/jnp.17.4.496","volume":"17","author":"JS Paulsen","year":"2005","unstructured":"Paulsen JS, et al. Depression and stages of Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci. 2005;17(4):496\u2013502.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"739_CR84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.30.4.293","volume":"30","author":"L Di Maio","year":"1993","unstructured":"Di Maio L, et al. Suicide risk in Huntington\u2019s disease. J Med Genet. 1993;30(4):293\u20135.","journal-title":"J Med Genet"},{"issue":"4","key":"739_CR85","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajmg.1320480412","volume":"48","author":"H Lipe","year":"1993","unstructured":"Lipe H, Schultz A, Bird TD. Risk factors for suicide in Huntingtons disease: a retrospective case controlled study. Am J Med Genet. 1993;48(4):231\u20133.","journal-title":"Am J Med Genet"},{"issue":"3","key":"739_CR86","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.psychres.2011.05.006","volume":"188","author":"HH Wetzel","year":"2011","unstructured":"Wetzel HH, et al. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res. 2011;188(3):372\u20136.","journal-title":"Psychiatry Res"},{"issue":"5","key":"739_CR87","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s11940-011-0140-y","volume":"13","author":"A Krishnamoorthy","year":"2011","unstructured":"Krishnamoorthy A, Craufurd D. Treatment of apathy in Huntington\u2019s disease and other movement disorders. Curr Treat Options Neurol. 2011;13(5):508\u201319.","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"739_CR88","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s002130000575","volume":"153","author":"N De Marchi","year":"2001","unstructured":"De Marchi N, Daniele F, Ragone MA. Fluoxetine in the treatment of Huntington\u2019s disease. Psychopharmacology. 2001;153(2):264\u20136.","journal-title":"Psychopharmacology"},{"issue":"3","key":"739_CR89","first-page":"216","volume":"15","author":"T Patzold","year":"2002","unstructured":"Patzold T, Brune M. Obsessive compulsive disorder in Huntington disease: a case of isolated obsessions successfully treated with sertraline. Neuropsychiatry Neuropsychol Behav Neurol. 2002;15(3):216\u20139.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"739_CR90","doi-asserted-by":"crossref","first-page":"Rrn1261","DOI":"10.1371\/currents.RRN1261","volume":"3","author":"K Anderson","year":"2011","unstructured":"Anderson K, et al. An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington\u2019s disease. PLoS Curr. 2011;3:Rrn1261.","journal-title":"PLoS Curr"},{"issue":"3","key":"739_CR91","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1176\/jnp.8.3.338","volume":"8","author":"NG Ranen","year":"1996","unstructured":"Ranen NG, et al. Sertraline in the treatment of severe aggressiveness in Huntington\u2019s disease. J Neuropsychiatry Clin Neurosci. 1996;8(3):338\u201340.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"739_CR92","doi-asserted-by":"crossref","first-page":"Rrn1259","DOI":"10.1371\/currents.RRN1259","volume":"3","author":"M Groves","year":"2011","unstructured":"Groves M, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington\u2019s disease. PLoS Curr. 2011;3:Rrn1259.","journal-title":"PLoS Curr"},{"issue":"4","key":"739_CR93","first-page":"347","volume":"6","author":"S Madhusoodanan","year":"1998","unstructured":"Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington\u2019s disease. Am J Geriatr Psychiatry. 1998;6(4):347\u20139.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"739_CR94","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/070674370404900617","volume":"49","author":"DP Seitz","year":"2004","unstructured":"Seitz DP, Millson RC. Quetiapine in the management of psychosis secondary to Huntington\u2019s disease: a case report. Can J Psychiatr. 2004;49(6):413.","journal-title":"Can J Psychiatr"},{"issue":"1","key":"739_CR95","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","volume":"47","author":"M Alpay","year":"2006","unstructured":"Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington\u2019s disease. Psychosomatics. 2006;47(1):70\u20132.","journal-title":"Psychosomatics"},{"issue":"3","key":"739_CR96","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3233\/JHD-150169","volume":"4","author":"K Correia","year":"2015","unstructured":"Correia K, et al. The genetic modifiers of motor onsetAge (GeM MOA) website: genome-wide association analysis for genetic modifiers of Huntington\u2019s disease. J Huntingtons Dis. 2015;4(3):279\u201384.","journal-title":"J Huntingtons Dis"},{"issue":"3","key":"739_CR97","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","volume":"162","author":"Genetic Modifiers of Huntington\u2019s Disease Consortium","year":"2015","unstructured":"Genetic Modifiers of Huntington\u2019s Disease Consortium. Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell. 2015;162(3):516\u201326.","journal-title":"Cell"},{"issue":"1","key":"739_CR98","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.drudis.2014.09.011","volume":"20","author":"BM Godinho","year":"2015","unstructured":"Godinho BM, et al. Delivering a disease-modifying treatment for Huntington\u2019s disease. Drug Discov Today. 2015;20(1):50\u201364.","journal-title":"Drug Discov Today"},{"issue":"11","key":"739_CR99","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/mds.26331","volume":"30","author":"KM Shannon","year":"2015","unstructured":"Shannon KM, Fraint A. Therapeutic advances in Huntington\u2019s disease. Mov Disord. 2015;30(11):1539\u201346.","journal-title":"Mov Disord"},{"issue":"1","key":"739_CR100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ncl.2014.09.003","volume":"33","author":"P Dayalu","year":"2015","unstructured":"Dayalu P, Albin RL. Huntington disease: pathogenesis and treatment. Neurol Clin. 2015;33(1):101\u201314.","journal-title":"Neurol Clin"},{"key":"739_CR101","unstructured":"Huntington Study Group. Announcement of CREST-E early study closure. 2014: HuntingtonStudyGroup.org ."},{"key":"739_CR102","unstructured":"Huntington Study Group. Announcement of 2CARE early study closure. 2012: HuntingtonStudyGroup.org ."},{"issue":"1","key":"739_CR103","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(14)70262-5","volume":"14","author":"Huntington Study Group Reach","year":"2015","unstructured":"Huntington Study Group Reach. H.D.I. Safety, tolerability, and efficacy of PBT2 in Huntington\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14(1):39\u201347.","journal-title":"Lancet Neurol"},{"issue":"3","key":"739_CR104","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bcp.12512","volume":"79","author":"SD Sussmuth","year":"2015","unstructured":"Sussmuth SD, et al. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease. Br J Clin Pharmacol. 2015;79(3):465\u201376.","journal-title":"Br J Clin Pharmacol"},{"key":"739_CR105","unstructured":"Achey M.A.B. Meet the compound: RP103 (cysteamine bitartrate delayed-release). 2015 [cited 2016; Available from: http:\/\/huntingtonstudygroup.org\/hd-insights\/meet-the-compound-rp103-cysteamine-bitartrate-delayed-release\/.]"},{"key":"739_CR106","unstructured":"Multicentric Trial of the Treatment of Huntington\u2019s Disease by Cysteamine (RP103). 2013 [cited 2016; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02101957.]"},{"issue":"3","key":"739_CR107","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JHD-140110","volume":"3","author":"J Corey-Bloom","year":"2014","unstructured":"Corey-Bloom J, et al. Disease modifying potential of glatiramer acetate in Huntington\u2019s disease. J Huntingtons Dis. 2014;3(3):311\u20136.","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"739_CR108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.08.014","volume":"232","author":"GM Pasinetti","year":"2011","unstructured":"Pasinetti GM, et al. Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington\u2019s disease and other neurodegenerative disorders. Exp Neurol. 2011;232(1):1\u20136.","journal-title":"Exp Neurol"},{"issue":"10 Pt A","key":"739_CR109","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.bbadis.2015.07.003","volume":"1852","author":"L Naia","year":"2015","unstructured":"Naia L, Rego AC. Sirtuins: double players in Huntington\u2019s disease. Biochim Biophys Acta. 2015;1852(10 Pt A):2183\u201394.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"739_CR110","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.53.5.1000","volume":"53","author":"B Kremer","year":"1999","unstructured":"Kremer B, et al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology. 1999;53(5):1000\u201311.","journal-title":"Neurology"},{"issue":"13","key":"739_CR111","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/mds.23236","volume":"25","author":"Huntington Study Group DOMINO Investigators","year":"2010","unstructured":"Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntington\u2019s disease. Mov Disord. 2010;25(13):2219\u201324.","journal-title":"Mov Disord"},{"issue":"5\u20136","key":"739_CR112","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","volume":"33","author":"JH Chan","year":"2006","unstructured":"Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol. 2006;33(5\u20136):533\u201340.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"739_CR113","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cge.12385","volume":"86","author":"C Kay","year":"2014","unstructured":"Kay C, et al. Personalized gene silencing therapeutics for Huntington disease. Clin Genet. 2014;86(1):29\u201336.","journal-title":"Clin Genet"},{"issue":"9","key":"739_CR114","doi-asserted-by":"crossref","first-page":"e107434","DOI":"10.1371\/journal.pone.0107434","volume":"9","author":"NH Skotte","year":"2014","unstructured":"\u2022 Skotte NH, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One. 2014;9(9):e107434. Article describing development of stable ASOs targeting SNPs found on a majority of mutant alleles to stop production of mhtt","journal-title":"PLoS One"},{"issue":"47","key":"739_CR115","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","volume":"49","author":"KT Gagnon","year":"2010","unstructured":"Gagnon KT, et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry. 2010;49(47):10166\u201378.","journal-title":"Biochemistry"},{"key":"739_CR116","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2009.04975.x","volume":"1175","author":"J Hu","year":"2009","unstructured":"Hu J, Matsui M, Corey DR. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci. 2009;1175:24\u201331.","journal-title":"Ann N Y Acad Sci"},{"issue":"23","key":"739_CR117","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1093\/hmg\/ddu349","volume":"23","author":"X Sun","year":"2014","unstructured":"Sun X, et al. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum Mol Genet. 2014;23(23):6302\u201317.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"739_CR118","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031\u201344.","journal-title":"Neuron"},{"issue":"12","key":"739_CR119","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"JB Carroll","year":"2011","unstructured":"Carroll JB, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178\u201385.","journal-title":"Mol Ther"},{"issue":"11","key":"739_CR120","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","volume":"29","author":"EJ Wild","year":"2014","unstructured":"Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington\u2019s disease: what\u2019s in the pipeline? Mov Disord. 2014;29(11):1434\u201345.","journal-title":"Mov Disord"},{"issue":"5","key":"739_CR121","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435\u201342.","journal-title":"Lancet Neurol"},{"key":"739_CR122","unstructured":"Ionis Pharmaceuticals, Inc. Safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-HTTRx in patients with early manifest Huntington's disease. Bethesda: National Library of Medicine (US); 2000. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02519036 ."},{"issue":"11","key":"739_CR123","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/mds.26020","volume":"29","author":"N Aronin","year":"2014","unstructured":"\u2022 Aronin N, DiFiglia M. Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord. 2014;29(11):1455\u201361. Review article describing in greater detail the function and limitations of various genetic approaches at gene silencing for HD","journal-title":"Mov Disord"},{"issue":"2","key":"739_CR124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2014.11.022","volume":"556","author":"A Kumar","year":"2015","unstructured":"Kumar A, et al. Huntington\u2019s disease: an update of therapeutic strategies. Gene. 2015;556(2):91\u20137.","journal-title":"Gene"},{"issue":"5","key":"739_CR125","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"LM Stanek","year":"2014","unstructured":"Stanek LM, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease. Hum Gene Ther. 2014;25(5):461\u201374.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"739_CR126","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4161\/cbt.9.5.10958","volume":"9","author":"K Rolle","year":"2010","unstructured":"Rolle K, et al. Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol Ther. 2010;9(5):396\u2013406.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"739_CR127","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/mt.2013.217","volume":"22","author":"J Moreno-Montanes","year":"2014","unstructured":"Moreno-Montanes J, et al. Phase I clinical trial of SYL040012, a small interfering RNA targeting beta-adrenergic receptor 2, for lowering intraocular pressure. Mol Ther. 2014;22(1):226\u201332.","journal-title":"Mol Ther"},{"issue":"45","key":"739_CR128","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","volume":"109","author":"M Garriga-Canut","year":"2012","unstructured":"Garriga-Canut M, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice. Proc Natl Acad Sci. 2012;109(45):E3136\u201345.","journal-title":"Proc Natl Acad Sci"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-017-0739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-017-0739-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-017-0739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T05:22:54Z","timestamp":1601788974000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-017-0739-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s11910-017-0739-9","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]},"article-number":"33"}}